Cance W G, Carey L A, Calvo B F, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival[J]. Ann Surg, 2002, 236(3):295.
[2]
Orlikova B, Legrand N, Panning J, et al. Anti-inflammatory and anticancer drugs from nature[J]. Cancer Treat Res, 2014, 159:123.
[3]
Hubalek M, Brunner C, Matth K, et al. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment[J]. Wien Med Wochenschr, 2010, 160(19/20):506.
[4]
Fu F, Hou Y, Jiang W, et al. Escin: inhibiting inflammation and promoting gastrointestinal transit to attenuate formation of postoperative adhesions[J]. World J Surgery, 2005, 29 (12):1614.
[5]
Wang X H, Xu B, Liu J T, et al. Effect of beta-escin sodium on endothelial cells proliferation, migration and apoptosis[J]. Vascul Pharmacol, 2008, 49(4/6):158.
[6]
Niu Y P, Li L D, Wu L M. Beta-aescin: a potent natural inhibitor of proliferation and inducer of apoptosis in human chronic myeloid leukemia K562 cells in vitro[J]. Leuk Lymphoma, 2008, 49(7):1384.
Nalepa G, Zukowska-Szczechowska E. Caspases and apoptosis: die and let live[J]. Wiad Lek, 2002, 55(1/2):100.
[9]
Saini K S, Loi S, de Azambuja E, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer[J]. Cancer Treat Rev, 2013, 39(8):935.
[10]
Li D, Shatos M A, Hodges R R, et al. Role of PKCα activation of Src, PI-3K/AKT, and ERK in EGF-stimulated proliferation of rat and human conjunctival goblet cells[J]. Invest Ophthalmol Vis Sci, 2013,54(8):5661.
Dhillon A S, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer[J]. Oncogene, 2007, 26(22): 3279.
[16]
Dehm S M, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation[J]. Biochem Cell Biol, 2004, 82(2): 263.
[17]
Machida K, Matsuda S, Yamaki K, et al. v-Src suppresses SHPS-1 expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells[J]. Oncogene, 2000, 19(13): 1710.
[18]
Yu C L, Meyer D J, Campbell G S, et al. Enhanced DNA-binding activity of a STAT3-related protein in cells transformed by the Src oncoprotein[J]. Science, 1995, 269(5220): 81.
[19]
Zhuang S, Schnellmann R G. A death-promoting role for extracellular signal-regulated kinase[J]. J Pharmacol Exp Ther, 2006, 319(3): 991.
[20]
Owonikoko T K, Khuri F R. Targeting the PI3K/AKT/mTOR Pathway[J]. Am Soc Clin Oncol Educ Book, 2013:395.
[21]
Garces C A, Cance W G. Neoadjuvant chemotherapy of breast cancer[J]. Am Surg, 2004, 70(7):565.
